Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned -7.40%, Advisor Class fund APDMX posted a return of -7.37%, and Institutional Class fund APHMX returned -7.35%, compared to a -7.12% return for the Russell Midcap Growth Index. US equities achieved solid Q4 gains, concluding a strong year. After a period of strong growth stock performance in 2023 and 2024, value stocks gained the lead in Q1 2025. In a risk-averse environment, investors shifted towards lower-volatility equities, especially in the utilities and consumer staples sectors, alongside those with higher dividend yields. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Artisan Mid Cap Fund highlighted stocks such as Illumina, Inc. (NASDAQ:ILMN). Illumina, Inc. (NASDAQ:ILMN) is a leading supplier of sequencing- and array-based solutions for genetic and genomic analysis. The one-month return of Illumina, Inc. (NASDAQ:ILMN) was 11.19%, and its shares lost 28.70% of their value over the last 52 weeks. On May 5, 2025, Illumina, Inc. (NASDAQ:ILMN) stock closed at $78.17 per share with a market capitalization of $12.371 billion. Artisan Mid Cap Fund stated the following regarding Illumina, Inc. (NASDAQ:ILMN) in its Q1 2025 investor letter: "We ended our investment campaigns inIllumina, Inc. (NASDAQ:ILMN), Best Buy and Datadog during the quarter. Illumina is a leading provider of next generation sequencing instruments for genetic testing. Genome sequencing has become more mainstream as costs have fallen, expanding within academic research and into high-value clinical diagnostic testing applications. However, rising concerns about funding cuts to the National Institute of Health and news that China will restrict Illumina’s business have overwhelmed the longer term thesis, leading us to exit the position."Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns A research facility with medical professionals surrounded by diagnostic equipment. Illumina, Inc. (NASDAQ:ILMN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge fund portfolios held Illumina, Inc. (NASDAQ:ILMN) at the end of the fourth quarter compared to 54 in the third quarter. Illumina, Inc.’s (NASDAQ:ILMN) fourth-quarter revenue reached $1.1 billion, surpassing expectations. While we acknowledge the potential of Illumina, Inc. (NASDAQ:ILMN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. Story Continues In another article, we covered Illumina, Inc. (NASDAQ:ILMN) and shared Patient Capital Opportunity Equity Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Here’s Why Artisan Mid Cap Fund Decided to Exit Illumina (ILMN)
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...